CYP2C19 testing within clinical practice: Focus on cardiomyopathy and stroke

Join speakers:

Dharmisha Chauhan, Lead Genomic Medicine Pharmacist, North Thames GMSA
Paul Wright, Consultant Cardiovascular Pharmacist, Bart’s NHS Trust 
Paresh Parmar, Lead Pharmacist Care of Older People, Stroke from Northwick Park Hospital

The role of CYP2C19 pharmacogenetic testing entered the NHS earlier this year through a drug called mavacamten, a first in class ATPase inhibitor licensed for the treatment of obstructive hypertrophic cardiomyopathy (oHCM). Clinicians are now utilising CYP2C19 testing to identify which patients will require a dose reduction prior to mavacamten treatment. In addition to this NICE are reviewing the role of CYP2C19 testing for stroke and though a final decision has not been made (expected Summer/Autumn 2024), it has started to generate conversations on what a pharmacogenetic testing pathway would look like for stroke patients and the wider implications of CYP2C19 testing.

The key topics which will be covered include:

• Introduction to CYP2C19 nomenclature;
• Implementation of CYP2C19 testing for mavacamten;
• The role of CYP2C19 testing for stoke;
• Enablers, barriers and challenges of implementing CYP2C19 testing across the NHS.

The recording is recorded in May 2024.